United Laboratories subsidiary, UBT251 injection (a Class 1 innovative drug), achieved near-20% weight loss in Phase II clinical trials
February 25, 2026
Source: drugdu
28
On February 24, United Laboratories (03933) issued an announcement stating that its wholly-owned subsidiary, United Biotechnology (Zhuhai Hengqin) Co., Ltd., has independently developed a Class 1 innovative drug. UBT251 injection has completed a Phase II clinical trial in overweight/obese patients in China.
This study included 205 obese or overweight patients with weight-related comorbidities. The participants had a baseline mean weight of 92.2 kg and a baseline mean BMI of 33.1 kg. The results showed that after 24 weeks of administration, the mean weight change from baseline was the highest in each of the UBT251 dose groups, reaching -19.7% (-17.5 kg), while the placebo group showed -2.0% (-1.6 kg).
Furthermore, UBT251 significantly improved key secondary endpoints such as waist circumference, blood glucose, blood pressure, and blood lipids compared to placebo, with good overall safety and tolerability, and no withdrawals due to adverse events occurred. The company will initiate a Phase III clinical trial in overweight/obese patients in China as soon as possible.
https://finance.eastmoney.com/a/202602243652758547.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Bio-Thera Solutions’ innovative drug, Darpubayimab injection, has had its marketing authorization application accepted by the NMPA February 25, 2026
- Dashi Pharmaceuticals licenses its migraine medication to NewCo in the United States. February 25, 2026
- Dongyangguang Pharmaceutical’s first anti-Nipah virus “lifesaving drug” has entered clinical trials, achieving a 100% mortality protection rate in animal prevention. February 25, 2026
- 34 million patients no longer rely on imported drugs February 25, 2026
- How far can GLP-1 go in the weight loss race? February 25, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
